Diminished cholesterol efflux mediated by HDL and coronary artery disease in young male anabolic androgenic steroid users

Diminished cholesterol efflux mediated by HDL and coronary artery disease in young male anabolic androgenic steroid users / Francis Ribeiro de Souza, Marcelo Rodrigues Dos Santos, Rafael Armani Porello, Guilherme Wesley Peixoto da Fonseca, Ana Luiza Carrari Sayegh, Thaís Pinheiro Lima, Fabiana Dias Ferreira, Tiago Franco de Oliveira, Maurício Yonamine, Liliam Takayama, Rosa Maria Rodrigues Pereira, Carlos Eduardo Negrão, Marisa Passarelli, Carlos Eduardo Rochitte, Maria Janieire de Nazaré Nunes Alves. - (Atherosclerosis (2019) 283 (April); p. 100-105).
- PMID: 30826541.
- DOI: 10.1016/j.atherosclerosis.2019.02.006


Anabolic androgenic steroids (AAS) have been associated with coronary artery disease (CAD). AAS abuse leads to a remarkable decrease in high-density lipoprotein (HDL) plasma concentration, which could be a key factor in the atherosclerotic process. Moreover, not only the concentration of HDL, but also its functionality, plays a pivotal role in CAD. We tested the functionality of HDL by cholesterol efflux and antioxidant capacity. We also evaluated the prevalence of CAD in AAS users.

Twenty strength-trained AAS users (AASU) age 29 ± 5 yr, 20 age-matched strength-trained AAS nonusers (AASNU), and 10 sedentary controls (SC) were enrolled in this cross-sectional study. Functionality of HDL was evaluated by 14C-cholesterol efflux and the ability of HDL in inhibiting LDL oxidation. Coronary artery was evaluated with coronary computed tomography angiography.

Cholesterol efflux was lower in AASU compared with AASNU and SC (20 vs. 23 vs. 24%, respectively, p < 0.001). However, the lag time for LDL oxidation was higher in AASU compared with AASNU and SC (41 vs 13 vs 11 min, respectively, p < 0.001). We found at least 2 coronary arteries with plaques in 25% of AASU. None of the AASNU and SC had plaques. The time of AAS use was negatively associated with cholesterol efflux.

This study indicates that AAS abuse impairs the cholesterol efflux mediated by HDL. Long-term AAS use seems to be correlated with lower cholesterol efflux and early subclinical CAD in this population.


Research / Study
12 February 2019
Alves, Maria Janieire Nazaré Nunes
Dos Santos, Marcelo Rodriques
Ferreira, Fabiana Dias
Fonseca, Guilherme Wesley Peixoto da
Lima, Thaís Pinheiro
Negrão, Carlos Eduardo
Oliveira, Tiago Franco de
Passarelli, Marisa
Pereira, Rosa Maria Rodrigues
Porello, Rafael Armani
Rochitte, Carlos Eduardo
Sayegh, Ana Luiza Carrari
Souza, Francis Ribeiro de
Takayama, Liliam
Yonamine, Maurício
Other organisations
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo - University of São Paulo Faculty of Medicine Clinics Hospital
Doping classes
S1. Anabolic Agents
Medical terms
Cardiovascular diseases
Health effects
Document category
Date generated
5 June 2019
Date of last modification
18 June 2019
  • Legal Source
  • Education
  • Science
  • Statistics
  • History
Country & language
  • Country
  • Language
Other filters
  • ADRV
  • Legal Terms
  • Sport/IFs
  • Other organisations
  • Laboratories
  • Analytical aspects
  • Doping classes
  • Substances
  • Medical terms
  • Various
  • Version
  • Document category
  • Document type
Publication period